GEN 1059
Alternative Names: BNT 314; GEN-1059Latest Information Update: 19 Jun 2025
At a glance
- Originator BioNTech; Genmab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 24 Apr 2025 Pharmacodynamics data from a preclinical study in Solid tumours released by BioNTech
- 01 Dec 2023 BioNTech plans a phase I/II trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease) in USA (IV, Infusion) (NCT06150183)